Droubi Sami, Aqsa Anum, Rehan Maryam, Dhar Meekoo
Department of Internal Medicine, Staten Island University Hospital, New York, New York, USA,
Department of Internal Medicine, Staten Island University Hospital, New York, New York, USA.
Chemotherapy. 2021 Feb 4:1-3. doi: 10.1159/000512499.
Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor. Palbociclib combined with endocrine therapy has shown promising results in hormone-receptor-positive (HR+) and human epidermal growth factor receptor-negative (HER-2-) breast cancer progression. We present a case of a woman with a history of infiltrating lobular cancer of the left breast, status post modified radical mastectomy 6 years prior, presenting with nodular erythematous lesions on the left arm and back. Histopathological examination confirmed the diagnosis of recurrent metastatic breast adenocarcinoma. She had complete resolution of cutaneous metastasis with 1 cycle of Palbociclib. We believe our case is unique as the resolution of cutaneous metastasis with 1 cycle of single-agent Palbociclib is rare. Furthermore, it highlights the importance of considering cutaneous metastasis as a possibility in patients with prior history of primary internal malignancy.
帕博西尼是一种细胞周期蛋白依赖性激酶（CDK）4/6抑制剂。帕博西尼联合内分泌治疗在激素受体阳性（HR+）和人表皮生长因子受体阴性（HER-2-）乳腺癌进展方面已显示出有前景的结果。我们报告一例有左侧乳腺浸润性小叶癌病史的女性病例，6年前接受改良根治性乳房切除术后，现左侧手臂和背部出现结节性红斑病变。组织病理学检查确诊为复发性转移性乳腺腺癌。她经1个周期的帕博西尼治疗后皮肤转移灶完全消退。我们认为我们的病例很独特，因为单药帕博西尼1个周期就使皮肤转移灶消退的情况很罕见。此外，它凸显了对于有原发性内脏恶性肿瘤既往史的患者，考虑皮肤转移可能性的重要性。
